Renovaro (RENB) Competitors $0.36 -0.02 (-4.90%) As of 01:28 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock RENB vs. DRUG, CRGX, IPHA, NBTX, TIL, SOPH, BTMD, KOD, NVCT, and INBXShould you be buying Renovaro stock or one of its competitors? The main competitors of Renovaro include Bright Minds Biosciences (DRUG), CARGO Therapeutics (CRGX), Innate Pharma (IPHA), Nanobiotix (NBTX), Instil Bio (TIL), SOPHiA GENETICS (SOPH), biote (BTMD), Kodiak Sciences (KOD), Nuvectis Pharma (NVCT), and Inhibrx (INBX). These companies are all part of the "pharmaceutical products" industry. Renovaro vs. Its Competitors Bright Minds Biosciences CARGO Therapeutics Innate Pharma Nanobiotix Instil Bio SOPHiA GENETICS biote Kodiak Sciences Nuvectis Pharma Inhibrx Renovaro (NASDAQ:RENB) and Bright Minds Biosciences (NASDAQ:DRUG) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their analyst recommendations, profitability, dividends, earnings, valuation, community ranking, institutional ownership, media sentiment and risk. Which has more risk & volatility, RENB or DRUG? Renovaro has a beta of 0.55, meaning that its stock price is 45% less volatile than the S&P 500. Comparatively, Bright Minds Biosciences has a beta of -5.75, meaning that its stock price is 675% less volatile than the S&P 500. Does the MarketBeat Community favor RENB or DRUG? Bright Minds Biosciences received 11 more outperform votes than Renovaro when rated by MarketBeat users. CompanyUnderperformOutperformRenovaroN/AN/ABright Minds BiosciencesOutperform Votes1191.67% Underperform Votes18.33% Does the media refer more to RENB or DRUG? In the previous week, Bright Minds Biosciences had 5 more articles in the media than Renovaro. MarketBeat recorded 6 mentions for Bright Minds Biosciences and 1 mentions for Renovaro. Renovaro's average media sentiment score of 1.87 beat Bright Minds Biosciences' score of 1.11 indicating that Renovaro is being referred to more favorably in the media. Company Overall Sentiment Renovaro Very Positive Bright Minds Biosciences Positive Is RENB or DRUG more profitable? Bright Minds Biosciences' return on equity of -5.85% beat Renovaro's return on equity.Company Net Margins Return on Equity Return on Assets RenovaroN/A -61.84% -48.07% Bright Minds Biosciences N/A -5.85%-5.68% Do insiders and institutionals have more ownership in RENB or DRUG? 71.4% of Renovaro shares are owned by institutional investors. Comparatively, 40.5% of Bright Minds Biosciences shares are owned by institutional investors. 21.7% of Renovaro shares are owned by company insiders. Comparatively, 42.7% of Bright Minds Biosciences shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term. Do analysts rate RENB or DRUG? Bright Minds Biosciences has a consensus price target of $83.25, suggesting a potential upside of 194.17%. Given Bright Minds Biosciences' stronger consensus rating and higher possible upside, analysts clearly believe Bright Minds Biosciences is more favorable than Renovaro.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Renovaro 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Bright Minds Biosciences 0 Sell rating(s) 0 Hold rating(s) 6 Buy rating(s) 2 Strong Buy rating(s) 3.25 Which has stronger valuation and earnings, RENB or DRUG? Bright Minds Biosciences is trading at a lower price-to-earnings ratio than Renovaro, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioRenovaroN/AN/A-$80.65M-$0.77-0.47Bright Minds BiosciencesN/AN/A-$2.06M-$0.36-78.61 SummaryBright Minds Biosciences beats Renovaro on 11 of the 15 factors compared between the two stocks. Get Renovaro News Delivered to You Automatically Sign up to receive the latest news and ratings for RENB and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding RENB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart RENB vs. The Competition Export to ExcelMetricRenovaroPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$61.62M$6.92B$5.61B$8.57BDividend YieldN/A2.54%5.28%4.17%P/E Ratio-0.388.6327.2219.81Price / SalesN/A265.57411.31154.51Price / CashN/A65.8538.3234.64Price / Book0.696.587.014.65Net Income-$80.65M$143.75M$3.23B$248.05M7 Day Performance16.87%1.52%-0.06%-0.15%1 Month Performance7.70%12.43%8.75%4.50%1 Year Performance-75.10%3.67%32.44%13.76% Renovaro Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)RENBRenovaro2.3064 of 5 stars$0.36-4.9%N/A-73.5%$61.62MN/A-0.3820Positive NewsGap DownDRUGBright Minds Biosciences3.3422 of 5 stars$28.32+9.1%$83.25+194.0%+2,552.3%$199.49MN/A-166.58N/APositive NewsAnalyst RevisionGap DownCRGXCARGO Therapeutics2.4255 of 5 stars$4.28+0.7%$15.00+250.5%-73.8%$197.35MN/A-1.00116Positive NewsIPHAInnate Pharma3.1576 of 5 stars$2.14-2.2%$11.00+413.8%-19.5%$197.35M$12.62M0.00220Positive NewsNBTXNanobiotix2.884 of 5 stars$4.13+0.8%$8.00+93.5%+8.3%$194.85M-$11.61M0.00100Short Interest ↓Gap UpTILInstil Bio2.6675 of 5 stars$29.65+10.0%$112.33+278.9%+248.6%$194.47MN/A-2.56410Short Interest ↑Gap DownHigh Trading VolumeSOPHSOPHiA GENETICS1.8135 of 5 stars$2.91-3.0%$6.80+133.7%-39.6%$194.06M$67.17M-2.67520News CoveragePositive NewsBTMDbiote3.8941 of 5 stars$3.54+2.3%$8.00+126.0%-40.4%$193.67M$199.38M13.62194KODKodiak Sciences4.232 of 5 stars$3.60+5.9%$9.00+150.0%+31.9%$189.95MN/A-0.9990Short Interest ↓NVCTNuvectis Pharma2.9702 of 5 stars$8.98-4.6%$17.00+89.3%+32.8%$187.63MN/A-7.748News CoveragePositive NewsINBXInhibrx2.9161 of 5 stars$12.96-3.8%N/A-13.3%$187.61M$200K0.11166Positive NewsUpcoming EarningsGap Down Related Companies and Tools Related Companies Bright Minds Biosciences Alternatives CARGO Therapeutics Alternatives Innate Pharma Alternatives Nanobiotix Alternatives Instil Bio Alternatives SOPHiA GENETICS Alternatives biote Alternatives Kodiak Sciences Alternatives Nuvectis Pharma Alternatives Inhibrx Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:RENB) was last updated on 6/13/2025 by MarketBeat.com Staff From Our PartnersYour Bank Account Is No Longer SafeWhat If Washington Declared That: YOUR Money ISN'T Actually Yours? Sounds insane, but that's exactly what ...Priority Gold | SponsoredUtah’s New Oil FindThe Real Reason 218,000 Acres Just Vanished The government just quietly leased 218,000 acres in the middle ...Stansberry Research | SponsoredThe End of Elon Musk…?The End of Elon Musk? Don't make him laugh. Jeff Brown has been hearing this same tired story for years, an...Brownstone Research | SponsoredWhy July 22nd Could Mean Big Changes for Social SecurityIn a stunning move, President Trump has authorized an AI-led transformation of federal agencies, including Soc...Altimetry | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredJuly 2025 Rule Change to Impact Retirement InvestorsThere's a massive change from a new rule going into effect this July. And it's one the Big Banks are alread...Premier Gold Co | SponsoredBanks aren’t ready for this altcoin—are you?Donald Trump just fast-tracked TWO major crypto bills with an August deadline! Your window of opportunity i...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Renovaro Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Renovaro With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy RENB Stock Free RENB Stock Alerts